Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...

“Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, announced today the publication in Clinical Cancer Research[1] of the CTC biomarker analysis from the PACE trial, a ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

The top 5 most-viewed videos of 2025 explored a range of topics, including data presented at major medical meetings, health ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...

The Korea Innovation Foundation (INNOPOLIS) successfully concluded its Global Demo Day and participation at GITEX Expand North Star 2025 in Dubai, introducing ten Korean R&D-driven startups to global ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...